profit from every $100 of sales.
$0$100
Annexon
$4.23+0.71% today
+46.9% in 1 year
1-year low $2.681-year high $6.96
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Annexon sold, what it kept, and what it did with the cash.
Sales went from $0 in 2022 to $0 in 2025, with -$207 million of profit last year.
SalesProfit
Annexon vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Annexon | No profit yet | ||
 Vertex Pharmaceuticals | 35.3× · Expensive | ||
 Moderna | No profit yet | ||
 Regeneron Pharmaceuticals | 21.1× · Fair price | ||
 CSL | 22.2× · Fair price |
AI analysis
An AI analyst reads Annexon's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 0 | 0 | 0 | 0 | |
| – | – | – | – | |
| -146 | -144 | -154 | -216 | |
| -143 | -142 | -151 | -214 | |
| -142 | -134 | -138 | -207 | |
| -2.60 | -1.77 | -1.01 | -1.34 | |
| – | – | – | – | |
| – | – | – | – | |
| – | – | – | – |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 285 | 298 | 350 | 278 |
| Cash | 140 | 225 | 49 | 162 |
| Total debt | 33 | 31 | 29 | 26 |
| Total liabilities | 54 | 47 | 57 | 66 |
| 231 | 251 | 293 | 212 | |
| 55 | 76 | 137 | 155 | |
| -43.6% | -40.3% | -37.8% | -71.9% | |
| -61.4% | -53.6% | -47.2% | -97.7% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -116 | -121 | -118 | -186 | |
| 7 | 0 | 0 | 0 | |
| -123 | -121 | -118 | -186 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 19 | 18 | 19 | 16 |
Valuation
- –
- –
- –
- 4.7×
- –
- –
- –
- -23.3%
- -25.8%
- 0.0%
Profitability
- 0.0%
- 0.0%
- 0.0%
- 0.0%
- -89.2%
- -56.0%
- -101.2%
- -74.7%
- -90.4%
- –
Growth
- –
- –
- −58.0%
- –
- +41.8%
Financial health
- 0.7×
- 0.12
- 9.7%
- –
- 6.35
- 6.35
- 0.00
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 1%of 948
Bottom 21%of 871
Bottom 3%of 985
What analysts expect
- Average price target
- $16.00
- Range
- $16.00 – $16.00
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 7, 2026 | -0.23 | -0.30 | +23.3% |
| Mar 30, 2026 | -0.28 | -0.32 | +12.5% |
| Nov 10, 2025 | -0.37 | -0.34 | −8.8% |
| Aug 14, 2025 | -0.34 | -0.36 | +5.6% |
| May 12, 2025 | -0.37 | -0.30 | −23.3% |
| Mar 3, 2025 | -0.33 | -0.28 | −17.9% |
| Nov 14, 2024 | -0.25 | -0.26 | +3.8% |
| Aug 12, 2024 | -0.23 | -0.23 | +0.0% |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
23No pass
Benjamin Graham
39No pass
Philip Fisher
33No pass
Peter Lynch
58No pass
Joel Greenblatt
0No pass
Charlie Munger
27No pass
Terry Smith
26No pass
Questions about Annexon
Is Annexon a good stock to buy?
A business with weak numbers that is not profitable yet. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Annexon AI analysis
What does Annexon do?
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune, neurodegenerative, and ophthalmic disorders. It is in Biotechnology.
Does Annexon pay a dividend?
No. Annexon does not pay a dividend at the moment.
Is Annexon stock halal?
Yes. Annexon passes our halal screen: its business is permitted and its debt is 3% of its market value, under the 30% limit. How we check
How has Annexon stock done over the past year?
Up 46.9% over the past twelve months, to $4.23. It traded between $2.68 and $6.96 and is 39.2% below its high.
Who are Annexon's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals and CSL. The peers table on this page compares their profit, growth and price with Annexon's.
Prices: daily closes to Nov 9, 2026. Fundamentals: company reports via invest-like data.